Investors in This Boom-and-Bust Sector Are Jumping Ship

The biotech space is in a downtrend today. But once that trend reverses, a massive surge higher could begin... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] Investors in This Boom-and-Bust Sector Are Jumping Ship By Brett Eversole --------------------------------------------------------------- "If you catch one biotech bull market, you may never have to work again." It's a phrase Steve Sjuggerud said to me more than a decade ago, not long after I began working with him. And it's true. Steve figured this out by watching the biotech mania during the dot-com boom. The entire sector soared more than 500% in less than two years back then. And it even outperformed the tech sector along the way. In other words, when biotech booms, it really booms. But it can bust as well. One of those busts is underway today. And investors are fleeing the space at breakneck speed. The good news is that once that trend reverses, another massive surge higher could begin. Let me explain... --------------------------------------------------------------- Recommended Links: [How to Put Guaranteed Income 'Under the Tree']( A regular guy from upstate New York retired years ahead of schedule thanks to ONE investing idea that doesn't involve stocks... options... or cryptocurrencies. The secret: a simple strategy for seeing double-digit annual income... AND triple-digit capital gains... with legal protections (even in an economic crisis). [Click here to learn more](. --------------------------------------------------------------- [The No. 1 Threat to Your Wealth in 2024]( He predicted the Lehman Brothers collapse, bitcoin's 2018 crash, and the Nasdaq's top in 2021. Now Dan Ferris is issuing an urgent new warning – a new AI threat expected to cost Americans $100 billion in the next 18 months. Even if you don't own a single AI stock you could still be a victim just by picking up the phone. Learn how to protect yourself immediately, [right here](. --------------------------------------------------------------- Given the year we've had, you'd expect biotech stocks to be performing well. But it's quite the opposite. The sector is down double digits this year. And it's down 33% from the 2021 high as well. In short, this boom-and-bust sector is going "bust." Between the losses and the length of the decline, investors have had enough. They're not waiting for a rebound... They're selling in droves. We can see it by looking at shares outstanding for the two largest biotech exchange-traded funds ("ETFs"): the iShares Biotechnology Fund (IBB) and the SPDR S&P Biotech Fund (XBI). As ETFs, these funds create and liquidate shares based on investor demand. So a falling share count means investors are becoming less interested in biotech stocks. And that's exactly where we are right now. Take a look... Shares outstanding between these two funds have collapsed in recent months. They're down by more than 20% since peaking late last year. And that's one of the largest declines in the past 15 years. More important, the two similar declines we've seen in that stretch were great times to buy... First, shares outstanding plunged through the financial crisis. They bottomed in late 2011. But biotech stocks more than doubled over the next two years. It was a similar story in 2020. Shares outstanding bottomed after falling for several years. Then, biotech stocks took off... And shares outstanding nearly doubled over the next 18 months. Now, we don't know if today's negative sentiment has bottomed yet. Even more folks could flee the sector before it turns around. But according to history, we'll want to keep a close eye on biotech right now. If sentiment bottoms and reverses, prices should follow suit. And it'll be time to put money to work. But again, we're not there yet. Still, it's worth remembering what Steve once said... If you catch one biotech bull market, you may never have to work again. The next biotech bull market appears to be setting up now. Once prices get moving higher, this is an area you should consider owning. Good investing, Brett Eversole Further Reading Biotech stocks have been struggling lately. But once the trend reverses, you'll want to be ready to find winners with outsized potential. A few basic clues can lead you to the types of "no contest" companies that stand out in this sector... [Learn more here](. "To be a proactive investor, you have to see the end goal and all the steps it takes to get there," Dave Lashmet writes. In the biotech space, it's crucial to look for companies that invest in the future. That's how these businesses build a lasting competitive advantage... [Read more here](. --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You're receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2023 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.